Truncated RAF kinases drive resistance to MET inhibition in MET-addicted cancer cells
Open Access
- 15 November 2014
- journal article
- research article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (1) , 221-233
Abstract
Constitutively active receptor tyrosine kinases (RTKs) are known oncogenic drivers and provide valuable therapeutic targets in many cancer types. However, clinical efficacy of RTK inhibitors is limited by intrinsic and acquired resistance. To identify genes conferring resistance to inhibition of the MET RTK, we conducted a forward genetics screen in the GTL-16 gastric cancer cell line, carrying MET amplification and exquisitely sensitive to MET inhibition. Cells were transduced with three different retroviral cDNA expression libraries and selected for growth in the presence of the MET inhibitor PHA-665752. Selected cells displayed robust and reproducible enrichment of library-derived cDNAs encoding truncated forms of RAF1 and BRAF proteins, whose silencing reversed the resistant phenotype. Transduction of naïve GTL-16 cells with truncated, but not full length, RAF1 and BRAF conferred in vitro and in vivo resistance to MET inhibitors, which could be reversed by MEK inhibition. Induction of resistance by truncated RAFs was confirmed in other MET-addicted cell lines, and further extended to EGFR-addicted cells. These data show that truncated RAF1 and BRAF proteins, recently described as products of genomic rearrangements in gastric cancer and other malignancies, have the ability to render neoplastic cells resistant to RTK-targeted therapy.Keywords
This publication has 48 references indexed in Scilit:
- Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancerNature, 2012
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)Nature, 2011
- Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanomaNature Medicine, 2010
- Cell Signaling by Receptor Tyrosine KinasesCell, 2010
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAFNature, 2010
- Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibitionMolecular Cancer, 2010
- Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytomaOncogene, 2009
- Tandem Duplication Producing a Novel Oncogenic BRAF Fusion Gene Defines the Majority of Pilocytic AstrocytomasCancer Research, 2008
- Exploiting orthologue diversity for systematic detection of gain-of-function phenotypesBMC Genomics, 2008
- The HER family and cancer: emerging molecular mechanisms and therapeutic targetsTrends in Molecular Medicine, 2007